Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-11-24-Speech-3-183"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2010-11-24"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"it"^^xsd:language2
lpv:document identification number	"en.20101124.15.3-183"2
lpv:hasSubsequent	lp_eu:2010-11-24-Speech-3-9702
lpv:speaker	lp:Vito Bonsignore2
lpv:spokenAs	member; Delegation to the Parliamentary Assembly of the Union for the Mediterranean (2010-03-10--2014-06-30)3 substitute; Special committee on the policy challenges and budgetary resources for a sustainable European Union after 2013 (2010-06-17--2011-06-30)3 unknown; Il Popolo della Libertà (2009-07-14--2014-01-22)3 member; Special Committee on the Financial, Economic and Social Crisis (2009-10-08--2011-07-31)3 substitute; BUDG (2009-07-16--2012-01-18)3 vice-chair; EPP (2009-07-14--2014-06-30)3 substitute; PECH (2010-03-10--2012-01-18)3 substitute; Delegation to the EU-Russia Parliamentary Cooperation Committee (2009-09-16--2014-06-30)3 member; Delegation for relations with the Mashreq countries (2009-09-16--2014-06-30)3
lpv:translated text	"I should like to congratulate the rapporteur, my colleague Mr Fjellner, on his work on this report. I voted in favour as I believe it is essential to guarantee patients access to information on prescription-only medicinal products. Both the European Parliament and patients’ organisations have for some time been asking for an adjustment to the current regulations which, as they stand, do not guarantee the necessary information. Indeed, technical development and the easy availability on the Internet of information on the use of medicinal products are too often shown to be illusory and untrue. I agree with the underlying spirit of this report, which aims to put the ‘patient’s right to know’ into the centre of the legislation and, consequently, recommends that pharmaceutical companies give patients some basic information. I therefore hope for greater certainty in the law, which often falls short, partly due to the different degrees to which the Member States have implemented the previous directive. The provisions relating to information on prescription-only medicinal products therefore need to be updated and new rules need to be adopted, promoting greater health literacy and involving the health industry to a greater extent in carrying out a fundamental role to improve public health."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph